Via an integration with Teva Pharmaceuticals, the new module will leverage digital therapeutics to improve outcomes for patients with respiratory diseases
ATLANTA -- November 17, 2022 -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today the launch of its new Respiratory Module, designed to give providers a more complete view of the patient in order to guide treatment decisions for those with respiratory diseases. As part of the new module, patient data from connected pulse oximeters and—via a newly announced collaboration with Teva Pharmaceuticals—digital inhalers will be integrated into healthcare provider workflows, enhancing respiratory care and population health management.
Over 500 million people globally suffer from respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In many cases, patients with these respiratory conditions also have cardiometabolic disorders like hypertension, obesity and diabetes, which can create additional health complications and lead to greater healthcare expenses. Rimidi’s Respiratory Module, which complements the company’s full suite of disease modules, allows providers to comprehend the full picture of the patient's disease status both in the clinic and at home. As a result, staff are better empowered and equipped to make personalized, predictive care decisions and improve outcomes.
“Given that chronic respiratory conditions like asthma and COPD share many similarities with the cardiometabolic conditions that Rimidi already supports, such as the burden of daily home self-management and complex treatment guidelines, launching respiratory as our newest disease module made sense,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Digital therapeutics, like the Digihaler® platform, are making new data available to clinicians in the management of complex diseases and we are thrilled to bring that data into the clinical workflow as part of our platform.”
“The digital therapeutics space is growing as healthcare continues to modernize, and our team is working hard to make the use of digital therapeutics seamless for healthcare providers and the patients they serve,” said Manny Montalvo, SVP, Head of Digital Health & Innovation at Teva Pharmaceuticals. “We’re excited to integrate with Rimidi and leverage our innovative technologies together to further fulfill our mission of improving the lives of patients.”
For more information on Rimidi’s Respiratory Disease Management Module visit www.rimidi.com/respiratory.
Created by doctors, Rimidi’s leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit rimidi.com and follow us on Facebook, Twitter and LinkedIn.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
About Teva Digital Health
Teva aims to be a global leader in personalized, predictive care, continuously investing in platforms and regulatory-compliant systems that will change the nature of digital health as we know it to improve the lives of patients across the world. By leveraging. Teva’s proprietary software platform Digihaler® – developed and maintained in house by a team of research specialists and programmers – is built into a series of FDA and EMA-approved inhalers, currently marketed in North America and Europe.
Alloy, on behalf of Rimidi
Recent News & Insights
The pandemic forever changed not only healthcare but also changed workplace culture. To support a …
As Rimidi anticipates the VIVE 2024 Digital Healthcare Conference in Los Angeles, we are fueled by …